We now spend on average $2+ billion to bring a single drug to market. Can we fix Eroom's law? General Control Founder Lada Nuzhna and Elliot Hershberg of Amplify Partners sat down with a16z's Jorge Conde for a conversation on the state of biotech. They discuss: - How increasing regulation is making clinical trials more challenging in the US - China's advantages in drug development - AI's potential to help us develop drugs more efficiently - How powerful new modalities could enable new companies to succeed - How we could create the right economic incentives for longevity drugs - The significance of GLP-1s to the biotech industry And more. Watch the episode on YouTube: @ladanuzhna @ElliotHershberg @JorgeCondeBio